KNSA

Kiniksa Pharmaceuticals International, plc

Healthcare · $5.8B market cap

We can't put a fair value on KNSA right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-32.4% a year✗

Equity per share growth10.2% a year✓

Sales growth50.9% a year✓

Free cash flow growth78.2% a year✓

Return on invested capital1.1%✗

Follow KNSA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Jul 15, 2026: no open-market purchases, 1 sale worth $369K and 36 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-03

Sold

$369K

Other filings

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-01

Award

$1.2M

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-01

Award

3,650 shares

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-01

Tax withholding

$438K

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-01

Option exercise

2,644 shares

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-01

Option exercise

2,362 shares

Show all 36 other filings

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-01

Option exercise

2,558 shares

Megna Michael R

CHIEF ACCOUNTING OFFICER · 2026-09-01

Option exercise

3,932 shares

Moat Ross

CHIEF OPERATING OFFICER · 2026-09-01

Award

$2.9M

Moat Ross

CHIEF OPERATING OFFICER · 2026-09-01

Award

9,250 shares

Moat Ross

CHIEF OPERATING OFFICER · 2026-09-01

Tax withholding

$318K

Moat Ross

CHIEF OPERATING OFFICER · 2026-09-01

Option exercise

2,457 shares

Moat Ross

CHIEF OPERATING OFFICER · 2026-09-01

Option exercise

1,740 shares

Moat Ross

CHIEF OPERATING OFFICER · 2026-09-01

Option exercise

1,611 shares

Moat Ross

CHIEF OPERATING OFFICER · 2026-09-01

Option exercise

2,477 shares

Paolini John F.